Are the new crop of early IO agents revving up to go or are the wheels coming off already?

Early stage product development in oncology is fraught with many difficulties once it gets into first-in-human testing in the  clinic.

Balancing activity and toxities to finesse the therapeutic window is just one of the challenges to consider during dose escalation trials.

There’s also figuring out where these agents might perform best, in which line of therapy, with which combination partner, or how about the optimal dose/schedule?

In this review we explore half a dozen new products with different targets and modalities and put them through their paces.  What does the analysis tell us?

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by